Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large decrease in short interest in July. As of July 31st, there was short interest totaling 16,980 shares, a decrease of 97.0% from the July 15th total of 569,675 shares. Based on an average daily trading volume, of 555,531 shares, the short-interest ratio is presently 0.0 days. Approximately 1.7% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

BJDX has been the subject of several recent analyst reports. Wall Street Zen upgraded Bluejay Diagnostics to a “sell” rating in a research note on Saturday, July 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Insider Activity

In related news, major shareholder Financial Lp Hrt bought 64,047 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was acquired at an average price of $1.51 per share, for a total transaction of $96,710.97. Following the transaction, the insider directly owned 126,993 shares of the company’s stock, valued at $191,759.43. This represents a 101.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is owned by institutional investors and hedge funds.

Bluejay Diagnostics Stock Performance

Bluejay Diagnostics stock traded up $0.08 on Tuesday, reaching $1.07. The company’s stock had a trading volume of 748,595 shares, compared to its average volume of 7,375,797. The business’s fifty day moving average price is $2.31 and its 200 day moving average price is $2.24. The company has a market cap of $1.10 million, a price-to-earnings ratio of -0.09 and a beta of 0.89. Bluejay Diagnostics has a twelve month low of $0.83 and a twelve month high of $16.68.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.